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Inorganic arsenic (InAs) is an established
human carcinogen. The main sources of
human exposure are through inhalation of
arsenic dust particles and ingestion from
drinking water. Inhalation of arsenic, main-
ly from occupational exposures, increases
the risk of lung cancer, and ingestion of
arsenic causes skin cancer, in addition to
other characteristic skin alterations such as
keratosis and hyperpigmentation (1). More
recent evidence indicates that ingested
arsenic can also increase the risk of develop-
ing lung, bladder, kidney, and liver cancers
(24). We have estimated that at the pre-
sent EPA arsenic water standard of 50 pg/l,
the internal cancer risks may be comparable
to those of environmental tobacco smoke
and radon in homes (5).
InAs can be ingested as either arsenite
[As(III)] or arsenate [As(V)]. Although
As(V) is less toxic, it is reduced biologically
to As(III) before methylation, which is con-
sidered the detoxification mechanism for
InAs (6,7). Two subsequent methylation
steps take place: the first one produces
monomethylarsonate (MMA), which is
then further methylated to dimethylarsinate
(DMA). Both MMA and DMA are consid-
ered less toxic and bind less to tissues than
InAs (6).
It has been postulated that decrease or
saturation of methylation capacity may lead
to a threshold for the carcinogenicity of
ingested InAs, given that methylation is
considered a detoxifying mechanism for
InAs (6,8,9). Under this assumption, as
exposure increases, one would expect to see
an increase in the proportion of InAs, with
a corresponding decrease in MMA and
DMA.
Several biological media have been
used to assess arsenic exposure in humans.
Because arsenic is cleared from the blood
in a few hours, the arsenic level in blood is
not considered a good indicator, especially
for low-level exposures (10,11). Although
it accumulates in hair and nails, surface
arsenic contamination in the form of sorp-
tion from external sources also occurs,
making arsenic concentrations measured in
these samples less accurate for assessing
dose (12). Urinary arsenic is generally
regarded as the most reliable indicator of
recent exposure to InAs and is used as the
main biomarker of exposure (11). In the
case of ingestion, studies show that around
60-75% of the dose is excreted in the
urine (6,7,13).
Although total urinary arsenic has been
used to assess InAs exposure, it is important
to differentiate InAs and its metabolites
from organic forms. In particular, certain
types of seafood contain arsenobetaine, a
much less toxic, organic form of arsenic
that is quickly excreted in the urine. A
recent meal of fish could lead to high mea-
surements of total arsenic (due to arsenobe-
taine), resulting in an erroneously high eval-
uation of InAs exposure. Using methods of
speciation analysis, InAs, MMA, and DMA
can be separated from other arsenic com-
pounds. Currently, the sum of these species
in urine constitutes the preferred measure of
exposure to InAs, and we henceforth refer to
this sum as total arsenic (TotAs). The rela-
tive proportions of urinary InAs, MMA, and
DMA have been used as a measure of
methylation capacity (14).
Previously we presented the results of
several studies reporting speciated urinary
arsenic measures and showed that popula-
tion studies do not support the methylation
threshold hypothesis (15). The relative per-
centages of InAs, MMA, and DMA aver-
aged approximately 15-20%, 10-15%, and
60-70%, respectively, across studies, and
there was no systematic increase in percent
InAs with increasing exposure. In contrast, a
large interindividual variability was noted,
independent of exposure level. However, the
studies were of different populations,
exposed to InAs from different sources, and
urinary measurements were performed by
different methods. In addition, urinary lev-
els did not exceed 400 pg/l, so the question
remained as to what happened in more
highly exposed groups, such as the
Taiwanese populations where high cancer
risks have been described. For example, the
medium exposure group in Taiwan had
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used drinking water with a weighted aver-
age concentration of around 500 pg/l,
which would result in urine levels above
those published for previous occupational
or environmental studies.
A more recent study in the state of
Nevada identified individuals drinking well
water containing arsenic levels >500 pg/l
(mean = 1300 pg/1), with corresponding
average urinary measurements of 750 pg/l
(16). They were compared to an age- and
sex-matched unexposed group in the same
area, with mean arsenic water and urine
levels of 16 pg/l and 68 pg/l, respectively.
This small study (n = 18 matched pairs)
did not find evidence of a methylation
threshold at these high levels; percentages
of InAs found for exposed and unexposed
groups were similar (19.5% versus 18.6%).
Recently attention has focused on the
relative distributions of MMA and DMA
in the urine by exposure levels. A study in
Mexico found a significant increase in the
proportion of MMA relative to DMA
among people drinking water with an
arsenic concentration of 400 pg/l, com-
pared to a control group at 19 pg/l.
Although the proportions of InAs did not
differ, the authors postulated that the sec-
ond methylation step was impaired in the
exposed individuals (17). Other investiga-
tors have proposed that the MMA:DMA
ratio may be a better indicator of the satu-
ration of the methylation pathway than the
percent of InAs (18).
The purpose of the study reported here
was to investigate arsenic methylation pat-
terns as reflected in urinary metabolites
among subjects chronically exposed to high
levels of arsenic from drinking water in
order to analyze the contribution of expo-
sure, as well as other factors, to methyla-
tion capacity. The study was part of a large
biomarker investigation conducted in two
Chilean towns with different arsenic levels
in their water supplies. This paper focuses
on a cross-sectional comparison of the rela-
tive proportions of urinary arsenic metabo-
lites (InAs, MMA, DMA, and MMA:
DMA) with respect to arsenic exposure, as
well as with respect to other variables such
as sex, smoking, and ethnicity.
Methods
Study population. Study subjects were resi-
dents of two towns located in the high
Atacama Desert of northern Chile (Fig. 1),
and they were mainly of Atacamefio ethnic
origin. The towns were selected based on
their levels of arsenic in drinking water,
identified through the results of a previous
study (19) and confirmed by subsequent
analysis before and during biological sam-
ple collection. The water sources derive
from rivers originating in the Andes
Mountains and the arsenic content varies
depending on the natural geological com-
position of the rivers' courses (20). San
Pedro, with 1600 inhabitants, constituted
the high-exposure town. San Pedro has tWo
sources of water supply. Water from the
Vilama River is piped to most homes and
contains 600-680 pg As/l. The San Pedro
River contains about 170 pg As/I and pass-
es through some parts of town as a canal to
irrigate nearby farms. Residents without
public water supplies use this water for
drinking purposes as well. Toconao, with a
population of about 360, was selected as
the low-exposure, control town, and is
located about 40 km from San Pedro. The
main source of water in Toconao is the
Jerez River, which serves most houses and
contains approximately 15 pg As/l.
We recruited study subjects through
public announcements and meetings and
by door-to-door invitations to participate.
Each prospective participant was first inter-
viewed by a local recruiter to ascertain age,
smoking status, duration of residence,
drinking water source, and interest in par-
ticipation. They were asked to participate if
they were at least 18 years of age and had
lived in the town for the last 3 months. As
the study progressed, participants from San
Pedro and Toconao were selected to be fre-
quency-matched on sex, age, and smoking
status. In addition, an effort was made in
San Pedro to enroll participants who
reported drinking tap water because they
were the most highly exposed.
The initial enrollment into the study
consisted of 124 participants in San Pedro
and 108 in Toconao. Each study subject
was interviewed regarding general demo-
graphic characteristics, tobacco smoking,
and alcohol drinking habits, dietary infor-
mation including fluid intake, and medical,
occupational, and residential histories. It
was not possible for interviewers to be
blinded with respect to town of residence
or to arsenic exposure because interviews
were done in each town and the contrast-
ing arsenic levels were widely known.
However, because biological samples were
identified only by code, urinary arsenic
speciation analyses were blinded.
Laboratory analysis. First morning
urine samples were obtained by providing
participants with precoded, sterilized
propylene bottles and written and verbal
instructions on how to obtain a clean sam-
ple. Samples were collected from partici-
pants the next morning and kept frozen in
the field laboratory at -20°C until they
were transported in dry ice to the
University of Washington in Seattle, where
they were analyzed for arsenic content.
Urine samples were assayed by hydride
generation atomic absorption (HGAA)
spectroscopy following a method detailed
by Crecelius (21). Briefly, InAs [As(III)
and As(V)], MMA, and DMA are reduced
to the corresponding arsine in a batch reac-
tor using sodium borohydride. The volatile
reduction products (arsine, methyl arsine,
and dimethyl arsine, respectively) are
removed by sparging with helium.
Entrained arsines are concentrated in a
chromosorb-filled cryogenic trap at liquid
nitrogen temperatures until all arsine-form-
ing arsenic in the sample has reacted. The
cryotrap is then allowed to warm, and the
collected arsines are separated based on dif-
ferential volatilization. The detection of the
separated volatile arsenic species is accom-
plished by atomic absorption spectroscopy
using a hydrogen microburner combustion
cell to convert arsines to elemental arsenic.
Detection limits for InAs, MMA, and
DMA were 0.5 pg/l, 1.0 pg/l, and 2.0 pg/l,
respectively, with corresponding replicate
precisions of 3%, 3%, and 10%. Creatinine
meaurements were also performed to allow
expression of TotAs in relation to urine
concentration.
Nine samples had an unusually low pro-
portion of methylated species. Replicates of
these samples were tested by spiking in the
laboratory with a mixture of known
amounts of InAs, MMA, and DMA, which
uncovered unusual and strikingly low
recoveries of DMA and, to a lesser degree,
MMA. It was conduded that for those sam-
ples the methylation assay suffered from
interference by an as-yet unidentified sub-
stance. An alternative method was derived
for these anomalous samples, which result-
ed in more complete recovery of the methy-
lated species, although slighdy lower recov-
ery for InAs. Due to differences in method-
ology and in recovery rates, we chose to
omit these samples from the methylation
study. We also omitted one other sample
from Toconao, an outlier with an unusually
Figure 1. Map of the study area [adapted from
Sancha et al. (53)].
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high MMA:DMA ratio of 2.4 (several stan-
dard deviations away from the mean (0.15)
for that town, possibly due to the fact that
the TotAs was very low (4.4 pg/i) and
species were close to their detection limits.
The recovery rates of urinary arsenic
species were calculated by running control
samples periodically with urine samples.
Because the weighted average recovery rates
(over 3 batches of 25, 120, and 19 control
samples each) were so close to 100%
(98.4%, 100.3%, and 100.1% for InAs,
MMA, and DMA, respectively), we did not
adjust the assay values of each metabolite.
To rule out any systematic differences
between the study subjects whose urine
samples were excluded and those that were
included, the general characteristics of the
two groups were compared. All but one of
the excluded subjects were from the low-
exposure town, and seven were women.
Otherwise, the 10 excluded subjects were
comparable in age, ethnicity, years of resi-
dence, years of education, smoking, and
drinking of alcoholic beverages.
During the study, samples were taken
from the various water supplies: tap water
from San Pedro and Toconao and water
from the San Pedro River, from which
some participants drank as well. Water
analyses were performed by HGAA accord-
ing to a procedure similar to that used for
urine samples and by a flow-injection
analysis method for combined arsine-form-
ing arsenic species (22).
Statistical analysis. We first compared
general characteristics of study participants
by town, including age, sex, ethnicity, edu-
cation, length of residence, smoking, and
drinking of alcoholic beverages. For the dis-
tribution analyses of urinary arsenic
metabolites, TotAs (InAs + MMA + DMA),
the percentages of InAs, MMA, and DMA,
and the ratio MMA:DMA were first calcu-
lated by town. We also examined metabo-
lite pattern distribution by reported water
source: tap, canal, other, or mixed (e.g., tap
water at home, canal water when working
near San Pedro canal). The mean and medi-
an of each group were derived by first calcu-
lating the individual percentage or ratio and
then averaging over each category.
TotAs was used as the measure of expo-
sure and was expressed both as a direct mea-
sure (pg As/l urine) and as a creatinine-
adjusted measure (pg As/g urinary creati-
nine). The mean urinary arsenic levels were
slightly higher when expressed as a function
of the urinary concentration of creatinine, a
commonly used method to correct for differ-
ences in urinary concentrations. However,
creatinine excretion can vary considerably by
age, sex, lean body mass, diet, and other fac-
tors and is not considered a reliable indicator
of urinary dilution, especially for spot sam-
ples (23). In some cases creatinine values are
used to identify possible outliers (e.g., very
dilute or very concentrated urine samples).
We examined the distribution of creatinine
in our study and found the mean concentra-
tion to be 998 mg/g, with 20 of the 220 par-
ticipants' urine samples either <300 mg/g or
>2000 mg/g (approximate values of the
lower and upper 5%). We compared the dis-
tribution of metabolites including and
excluding these samples and found no essen-
tial difference. For the regression analyses
described below, we compared the results
using the unadjusted and adjusted arsenic
urine concentrations (pg/l and pg/g creati-
nine) and found them to be similar. In light
of the problems associated with creatinine
measurements and the similarities in the
results using adjusted or unadjusted values,
we decided to use the unadjusted urine mea-
surements expressed as pg As/l urine.
We investigated various factors by uni-
variate comparisons in relation to their pos-
sible association with metabolite distribu-
tion. Those considered relevant were then
entered into multiple regression analyses to
assess the contribution of each factor to the
dependent variables: percent InAs, percent
MMA, percent DMA, and MMA:DMA.
Indicator (dummy) variables were used for
dichotomous variables such as sex and
town of residence. Statistical analyses were
computed using Stata 4.0 software (24).
To examine the relationship of ethnici-
ty to arsenic metabolite distribution pat-
terns, we performed a separate analysis on a
subsample of the study population restrict-
ed to participants of Atacamefio and
European descent. These two groups con-
stituted most of the study subjects (80%)
and excluded those reporting other (speci-
fied or unspecified) or unknown ethnicity.
Results
The final study sample consisted of 122
study subjects in San Pedro and 98 in
Toconao; general characteristics of the sub-
jects are shown in Table 1. Two subjects,
one from each town, were excluded
because of incomplete participation (no
first morning urine sample). Ten were
excluded from the final analysis because of
irregularities in the urinary speciation assay
as explained above (one from San Pedro,
nine from Toconao).
Participants from both towns were gen-
erally quite similar, with comparable distri-
butions by sex, age, and educational level
(Table 1). The percentages of persons who
smoked or drank alcohol were also quite
similar. It was common for people to
report smoking or drinking occasionally, so
we also compared smokers who smoked at
least one cigarette a day to nonsmokers and
drinkers who consumed at least one drink a
week to nondrinkers [one drink was
defined as 12 oz. of beer, 4 oz. of wine, 1
oz. of liquor, or 8 oz. of aloja (aloja is an
alcoholic beverage made from fermented
pods of the Algarrobo tree)]. Although the
overall proportion of smokers was similar
in both towns (28% in San Pedro, 31% in
Toconao), both men and women in San
Pedro smoked almost 3 times as many ciga-
rettes as those in Toconao (7.2 versus 2.6
cigarettes per day for men, 5.7 versus 2.0
for women). Similarly, the proportion
reporting consumption of alcoholic bever-
ages was almost identical in the two towns
(57% and 56%); however, men drank
about four times more drinks per week
than women, and men in San Pedro drank
about 75% more than those in Toconao.
The ethnic composition and length of
residence varied somewhat between the two
towns. Although the proportions of
Table 1. General characteristics of study subjects
by town
Characteristic San Pedro Toconao
No. of subjects (%)
Total 122 98
Male 69 (57) 52 (53)
Female 53 (43) 46 (47)
Mean age, years (range)
Male 42.2 (20-74) 42.4 (19-75)
Female 40.1 (18-81) 40.1 (22-70)
Total 41.2 (18-81) 41.3 (19-75)
Mean residence, 20.0 (0.2-81) 27.9 (0.2-70)
years (range)
<5 13% 12%
25to <15 29% 23%
.15 58% 65%
Mean education, 7.2 (0-19) 7.7 (0-17)
years (range)
Ethnicity (%)
Atacamenos 91 (75) 71 (72)
Aymara/Mapuche 5 (4) 4 (4)
European 13 (11) 3 (3)
Other 8 (6) 12 (12)
Unknown 5 (4) 8 (8)
Smokers (%)
All 34 (28) 30 (31)
Male 22 (32) 22 (43)
Female 12 (23) 8 (17)
Smokers of .1
cigarette/day
(mean cigarettes/day)
Male 15 (7.2) 13 (2.6)
Female 9 (5.7) 3 (2.0)
Drink any alcohol (%)
All 70 (57) 55 (56)
Male 50 (72) 43 (83)
Female 20 (38) 12 (26)
Drinkers of .1 drink/week
(mean drinks/week)
Male 47 (15.8) 33 (8.8)
Female 13 (2.8) 1 (2.0)
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Atacamefios and other indigenous groups
(Aymara and Mapuche) were quite similar,
in San Pedro 11% reported being of
European descent, whereas in Toconao
only 3% did. Similarly, 10% of San Pedro
residents classified themselves as "other or
unknown," compared to 20% in Toconao.
The average length of residence was shorter
in San Pedro (20 versus 28 years) but was
quite long in both, with similar ranges.
The results of arsenic water analyses
conducted during the study period for the
three main water sources were within the
ranges reported previously (19,20). The
arsenic concentrations in San Pedro from
tap water (from the Vilama River) and
from canal water (San Pedro River) were
670 pg/l and 134 pg/l, respectively, while
that from the tap water in Toconao was 13
jig/l. The arsenic of the different water
sources was all inorganic, but the analytical
method we used did not distinguish As(V)
from As(III). However, previous analysis of
water samples from the same sources found
50
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that practically all of it was As(V) (19).
TotAs and the metabolite distributions
by town of residence are shown in Table 2.
In San Pedro the mean TotAs was about
10 times that of Toconao (583 pg/l and 61
pg/l, respectively). Four people reported
drinking only San Pedro canal water (mean
TotAs = 238 pg/l), and 18 reported drink-
ing from mixed sources, although their
TotAs levels were similar to those using
only tap water (545 pg/l).
The average TotAs concentration of
people drinking water from Toconao was
somewhat higher than the concentration
found in the water, presumably due to the
contribution from other sources (e.g., food
Table 2. Levels and relative distributions of urinary arsenic species, by town
San Pedro (n = 122) Toconao (n = 98)
Measure Mean SD Range Median Mean SD Range Median
Total As (pg/I) 583 347 61-1,893 482 61 41 6-267 49
Adjusted total 637 352 45-2,145 592 68 41 21-306 58
(pg As/g
creatinine)
InAs (pg/I) 108 76 5-374 91 8.7 7.2 1.2-41.0 6.6
MMA (pg/I) 91 66 4-329 73 6.1 4.3 0.9-23.0 4.8
DMA (pg/I) 385 234 43-1,225 320 45.8 33.5 3.8-246 39.1
%InAs 18.4 6.1 5.6-38.8 18.2 14.9 5.7 3.6-31.4 14.2
%MMA 15.0 5.5 1.7-30.6 14.8 10.6 4.2 3.1-23.9 9.7
%DMA 66.6 9.9 42.0-92.6 67.1 74.5 8.6 51.2-92.4 75.8
MMA:DMA 0.24 0.12 0.019-0.68 0.23 0.15 0.08 0.034-0.47 0.13
Abbreviations: InAs, inorganic arsenic; MMA, monomethylarsonate; DMA, dimethylarsinate.
Is 40
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Figure 2. Distribution of percent inorganic arsenic, percent monomethylarsonate (MMA), percent dimethylarsinate (DMA), and MMA:DMA by total urinary
arsenic levels for all the study participants from both towns.
Environmental Health Perspectives * Volume 104, Number 6, June 1996 623
Articles * Hopenhayn-Rich et al.
Table 3. Urinary arsenic metabolite distribution by various factors
Mean (SD)
San Pedro
Toconao
p-valuea
Male
Female
p-valuea
Atacameno
European
p-valuea
No
.1/day
p-valuea
No
>1/week
p-value8
Length of residence (years)
<5
25 to <1 5
>15
p-value
(test for trend)
Age groups (years)
<30
.30 to <50
.50
p-value (test for trend)
n Total (pg/I)
122 583 (347)
98 61 (41)
%InAs
18.4 (6.1)
14.9 (5.7)
<0.001
%MMA
15.0 (5.5)
10.6 (4.2)
<0.001
%DMA
66.6 (9.9)
74.5 (8.6)
<0.001
MMA:DMA
0.24(0.12)
0.15 (0.08)
<0.001
121 381 (397) 17.1 (6.0) 14.4 (5.9) 68.5 (10.5) 0.23(0.13)
99 314 (326) 16.4 (6.3) 11.5 (4.3) 72.0 (9.4) 0.17 (0.09)
0.43 <0.001 <0.001 <0.001
162 371 (390) 16.8(6.1)
16 325 (210) 18.3 (5.6)
0.34
12.6 (4.8)
17.2 (6.9)
<0.001
70.6 (9.4)
64.5 (11.0)
0.015
0.19 (0.10)
0.30 (0.16)
<0.001
156 354 (379) 16.3 (6.2) 12.4 (5.1) 71.3 (9.9) 0.18 (0.10)
41 392 (370) 18.8 (5.4) 15.9 (5.9) 65.2 (10.1) 0.26 (0.14)
0.018 <0.001 <0.001 <0.001
95 341 (379) 15.4 (5.5)
94 394 (364) 17.8 (6.2)
0.006
28 307 (306)
57 411 (428)
135 340(370)
56 355 (365)
96 381 (401)
68 303 (318)
18.6 (5.9)
17.6 (5.8)
16.1 (6.3)
0.01
18.0 (5.1)
17.1 (6.9)
15.4 (5.6)
0.01
12.5 (4.8)
14.1 (6.0)
0.048
15.6 (5.9)
14.3 (5.6)
12.1 (5.0)
<0.01
14.4 (5.2)
12.9 (5.5)
12.3 (5.4)
0.03
72.0 (9.2)
68.2 (10.4)
0.007
65.8 (9.7)
68.1 (9.3)
71.8 (10.2)
<0.01
67.6 (8.9)
70.1 (10.7)
72.2 (9.9)
0.01
0.18 (0.09)
0.22 (0.13)
0.018
0.25 (0.13)
0.22 (0.12)
0.18 (0.10)
<0.01
0.23 (0.12)
0.20 (0.12)
0.18 (0.11)
0.02
Abbreviations: InAs, inorganic arsenic; MMA, monomethylarsonate; DMA, dimethylarsinate.
at-test.
Table 4. Multiple linear regression results using %InAs, %MMA, %DMA, and MMA:DMA as the depen-
dent variables (n = 217)
Predictor variables Coefficient SE p-value 95% Cl
% InAs (l = 0.10)
Total arsenic (pg/I) 0.0029 0.0011 0.011 0.00067-0.0051
Sex (male vs. female) 0.61 0.85 0.474 -1.06-2.28
Age (years) -0.45 0.032 0.169 -0.110.019
Length of residence (years) -0.051 0.027 0.061 -0.10- -0.023
Smoking (cigarettes/day) 0.10 0.134 0.448 -0.16-0.37
Alcohol (drinks/week) -0.017 0.030 0.56 -0.075-0.041
% MMA(R2= 0.30)
Total arsenic (pg/I) 0.0039 0.00086 <0.001 0.022-0.0056
Sex (male vs. female) 2.76 0.66 <0.001 1.47-4.06
Age (years) 0.0042 0.025 0.867 -0.045-0.053
Length of residence (years) -0.072 0.021 0.001 -0.11- -0.31
Smoking (cigarettes/day) 0.33 0.10 0.002 0.13-0.54
Alcohol (drinks/week) -0.039 0.022 0.089 -0.084-0.0060
% DMA (R2= 0.23)
Total arsenic (pg/I) -0.0068 0.0017 <0.001 -0.010- -0.0034
Sex (male vs. female) -3.38 1.30 0.010 -5.93- -0.82
Age (years) 0.040 0.049 0.415 -0.057-0.14
Length of residence (years) 0.12 0.041 0.003 0.041-0.20
Smoking (cigarettes/day) -0.43 0.21 0.036 -0.84- -0.029
Alcohol (drinks/week) 0.056 0.045 0.219 -0.033-0.14
MMA:DMA (R2 = 0.28)
Total arsenic (pg/I) 0.000079 1.9 (x 10-5) <0.001 4.1-11.3 (x10-5)
Sex (male vs. female) 0.053 0.014 <0.001 0.024-0.081
Age (years) 4.91 (x10-7) 0.00054 0.999 -0.0011-0.0011
Length of residence (years) -0.0014 0.00045 <0.002 -0.0023- -0.00050
Smoking (cigarettes/day) 0.0081 0.0023 <0.001 0.0037-0.013
Alcohol (drinks/day) 0.00060 0.00050 0.226 -0.0016-0.00038
Abbreviations: InAs, inorganic arsenic; MMA, monomethylarsonate; DMA, dimethylarsinate.
and recent consumption of water in anoth-
er town). Given the much lower arsenic
levels in Toconao water, these factors
would contribute a greater proportion of
the total than in San Pedro, where water
was the overriding arsenic source.
The proportions of InAs and MMA
were slightly higher in San Pedro than
Toconao (18% versus 15% and 15% ver-
sus 11%, respectively), with a correspond-
ing inverse relationship for DMA (67%
versus 75%). This resulted in a greater
MMA:DMA ratio (0.24 versus 0.15). The
association between the distribution of
metabolites and TotAs levels across the
entire study population is illustrated graph-
ically in Figure 2. No clear, consistent pat-
tern of increase in percent InAs is evident;
there is a wide range of interindividual
variation. The very slight positive trend for
percent MMA and the negative relation-
ship with percent DMA can be synthesized
in the ratio ofMMA:DMA.
The distribution of arsenic metabolites
by factors other than exposure is presented
in Table 3. We compared nonsmokers to
those that smoked at least one cigarette per
day, and for alcohol we compared non-
drinkers to those that drank at least one
drink (as defined above) per week.
The proportions of metabolites were
significantly different (although the differ-
ences were small) for most variables pre-
sented. The greatest differences were
observed in the ratio of MMA:DMA, with
higher ratios for men (0.23) and for smok-
ers (0.26), and lower ratios for women
(0.17) and Atacamefios (0.19). Increasing
age and length of residence were associated
with decreasing MMA:DMA, and a smaller
but positive association was found for alco-
hol consumption.
Given the effects of these variables on the
distribution of arsenic metabolites, they were
all included in the regression analyses.
Although age and length of residence were
both associated with metabolite distribution
(Table 3), as expected, they were also corre-
lated with each other (r = 0.5, p<0.0001).
When they were entered together in a regres-
sion model including TotAs, age was not a
good predictor, but length of residence was
associated with all the metabolite outcome
measures. Table 4 shows the models for each
of the four dependent variables assessed. For
percent InAs, TotAs was significant, but the
coefficient was quite small (0.0029%), pre-
dicting about a 1% increase for a 500 pg/l
increase in TotAs. Smoking and gender were
not statistically significant. Length of resi-
dence was associated with a decrease in per-
cent InAs, although the magnitude of the
coefficient was small (-0.05% per year).
With respect to the methylated metabo-
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lites, TotAs, smoking, sex, and length of res-
idence were all contributing factors, whereas
alcohol and age showed no clear association.
By focusing on the MMA:DMA ratio, the
linear regression analysis predicted that a
500 pg/l increase in TotAs would result in a
0.04 change in the ratio, comparable but
somewhat lower than the difference found
between Toconao and San Pedro (0.15 ver-
sus 0.24; Table 2). However, when the
regression analysis was restricted to TotAs
levels <500 pg/l, the predicted change rose
to 0.13 for a 500 pg/l increase, but the coef-
ficient was small and not significant for the
model including TotAs >500 pg/l (these
models not shown). This suggests that there
is an increasing trend in MMA:DMA with
increasing exposure up to around 500 pg/l
TotAs, which then levels off and is unaffect-
ed by further increases in TotAs.
Smoking 10 cigarettes a day had an
effect on MMA:DMA (0.08 decrease), as
did being male (0.05 decrease). For length
of residence, the analysis predicted that a
negative change in MMA:DMA of 0.07
would be expected for 50 years of residence
(50 x -0.0014).
When location rather than TotAs was
used as an exposure indicator (Table 5), the
other variables remained quite similar, but
location contributed to a 0.081 change in
MMA:DMA (similar to the difference of
0.09 in the comparison of towns in Table
3). When the analysis was restricted to the
176 individuals of European or Atacamefio
descent, ethnicity (being Atacamefio)
proved to be the strongest predictor of the
model, with a coefficient of 0.076, but
there was little change in the rest of the
variables.
Discussion
In this study, the mean percentages of uri-
nary InAs were within the ranges described
for two other populations chronically
exposed to high levels of arsenic in drink-
ing water, one in the state of Nevada, USA
(16), and one in the Region Lagunera,
Mexico (17). Percentages of urinary InAs
were also within the range of a number of
studies including arsenic exposures of back-
ground, occupational, environmental, and
experimental groups (15).
Although the mean percent InAs was
slightly higher in San Pedro than in
Toconao, the 3.5% difference was quite
small given the difference in mean TotAs
of about 500 pg/l between the two towns,
and its biological significance is unclear. In
the regression analysis the percent InAs was
associated with TotAs, but the small mag-
nitude of the coefficient (1.4% increase in
percent InAs for a 500 pg/l increase in
TotAs) suggested only a weak effect, and
Table 5. Multiple linear regression: additional models
Predictor variables Coefficient SE p-value 95% Cl
MMA:DMA, using location (San Pedro vs. Toconao) as exposure measure (n = 217; R2 = 0.33)
Location 0.081 0.014 <0.001 0.054 - 0.11
Sex (male vs. female) 0.060 0.014 <0.001 0.033 - 0.087
Age (years) -0.00040 0.00053 0.455 -0.0014 - 0.00065
Length of residence (years) -0.0010 0.00044 0.026 -0.0019 - -0.00012
Smoking (cigarettes/day) 0.0074 0.0022 0.001 0.0030 - 0.012
Alcohol (drinks/week) -0.00087 0.00048 0.071 -0.0018 - 0.000077
MMA:DMA, restricting analysis to subjects of Atacameno and European ethnic origin (n = 176; R2 = 0.31)
Total arsenic (pg/I) 0.000068 0.000019 <0.001 0.000031-0.00010
Sex (male vs. female) 0.044 0.015 0.003 0.016 - 0.073
Age (years) -0.000081 0.00058 0.891 -0.0012 - 0.0011
Length of residence (years) -0.0014 0.00046 0.003 -0.0023 - -0.00050
Smoking (cigarettes/day) 0.0048 0.0024 0.049 0.000020 - 0.0094
Alcohol (drinks/week) -0.00048 0.00046 0.297 -0.0014 - 0.00043
Ethnicity 0.076 0.025 0.003 0.027 - 0.12
(European vs. Atacameno)
Abbreviations: InAs, inorganic arsenic; MMA, monomethylarsonate; DMA, dimethylarsinate.
lessened after adjustment for other factors.
In contrast, the much larger interindividual
variability of about 20% for any given
exposure level suggests that factors other
than arsenic exposure have an overall
greater role in determining the distribution
of metabolites. No evidence of a threshold
or saturation phenomenon was observed in
this population, which included several
individuals having TotAs levels well over
1000 pg/l.
With respect to the relative distribu-
tions of MMA and DMA, the differences
were larger, with an MMA:DMA ratio in
San Pedro more than 1.5 times that found
in Toconao (0.24 versus 0.15). This is con-
sistent with the results of the only other
study, that, to our knowledge, has exam-
ined MMA:DMA ratios in similarly con-
trasting exposure groups (17).
After controlling for exposure, other
factors were associated with a higher
MMA:DMA ratio, including smoking. The
effect of smoking may be related to compe-
tition between arsenic and some of the
many chemicals found in cigarette smoke
for common detoxification pathways or fac-
tors. For example, glutathione (GSH) is
involved in several steps of InAs metabo-
lism (25,26) and is likely to play a part in
the detoxification of several polycyclic aro-
matic hydrocarbon epoxides generated
from cigarette smoke (27). Experimental
studies have shown an elevation in GSH in
response to arsenic insult (28), and levels of
GSH are higher in the bladder tissue of
smokers compared to nonsmokers (29). In
both cases, the increase in GSH is likely to
be a response caused by increased exposure
to toxins. On the other hand, pretreatment
with GSH depletors impairs arsenic methy-
lation in animal tissue (30-32). While a
higher MMA:DMA ratio suggests modula-
tion of the second methylation step, and
the animal studies have suggested that
GSH depletion mainly affects the first
methylation reaction, these inconsistencies
may be due to differences in arsenic methy-
lation that exist between animals and
humans. Alternatively, the detoxification of
arsenic and tobacco carcinogens may com-
pete for other necessary substrates; for
example, binding sites in nonspecific pro-
teins as described for arsenic (33), and/or
enzyme systems such as glutathione or
methyl transferases.
The sex-related difference in the relative
proportions of MMA and DMA was also
reported in the recent study in Mexico (34),
but there is no clear explanation for this
finding. Although women appear to be bet-
ter arsenic methylators than men, the rele-
vance of this difference to arsenic-related
health effects is unknown. Another example
of a gender difference in the handling of
arsenic comes from an in vitro study in the
arsenical area of Mexico that found that
impaired proliferation was greater in lym-
phocytes from arsenic-exposed women than
from exposed men (35).
Length of residence showed a positive
effect on the distribution of all the metabo-
lites, but age did not affect distribution
when duration of residence was controlled
for. This suggests that an adaptation
response may provide a slight improvement
in methylation ability.
Ethnicity was a predictive factor:
Atacamefios had a lower MMA:DMA ratio
compared to subjects of European descent.
The level of exposure in San Pedro is similar
to that of the medium exposure group in
Taiwan, where overt signs of arsenicism
such as keratosis, hyperpigmentation, and
skin cancer were apparent. A previous study
found that residents of San Pedro had an
increased prevalence of white spots on their
skin compared to other towns in the area
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with lower water arsenic levels, but more
serious skin alterations were not observed
(19). The Atacamefio people have lived in
the region for 11,000 years (36), and studies
of mummies buried in the area up to 3000
years ago have revealed high arsenic concen-
trations in their internal organs (37). All
other known populations exposed to high
arsenic drinking water have been exposed
for much shorter time periods: the
Taiwanese for about 70 years (4), the
Chilean population of Antofagasta (mainly
of Spanish descent) for about 15 years (38),
the Argentine population for less than 150
years (39), and the more recendy described
residents of West Bengal in India for about
30 years (40). All but the Atacamefios have
shown characteristic keratosis and skin can-
cer. The question remains whether some
characteristic of the Atacamefio skin renders
it inherently more resistant to these alter-
ations, or whether some other evolutionary
adaptation over thousands of years has made
Atacamenios less susceptible to arsenic, and if
so, whether this protective mechanism is
related to methylation capacity.
A possible hypothesis that could explain
such an adaptation relates to Chagas dis-
ease, endemic in many parts of South
America including the Atacama Desert. The
infection is transmitted by the vinchuca
bug, a vector of the parasite Trypanosoma
cruzi (41), of the same family as the African
trypanosome that causes sleeping sickness,
which was traditionally treated with arseni-
cal drugs. Arsenic inhibits trypanothionine
disulfide reductase, a GSH equivalent in
African trypanosomes necessary for their
survival (42). If the South American try-
panosome has a similar enzymatic system, it
is plausible that over time the Atacamefios
developed a resistance to arsenic, as it pro-
tected against the consequences of Chagas
infection [which includes reproductive
effects such as congenital abnormalities,
abortion, and stillbirths (41)], leading to a
selective survival of those more capable of
tolerating the toxic effects of arsenic.
Most of the findings in this study are
related to variations in the MMA:DMA
ratio, and the significance of these differences
by factors such as arsenic exposure, sex, eth-
nicity, and smoking is not clear and needs
further investigation. Experimental studies of
rat liver cytosol indicate that for high expo-
sures, InAs inhibits the second methylation
step, leading to an accumulation of MMA
(32), which could partly account for the
MMA:DMA differences by exposure levels.
One possible explanation is the binding of
InAs to a dimethyltransferase involved in the
second methylation step (26).
Given the known relative genotoxicities
of InAs, MMA, and DMA (roughly
3000:2:1) (43) and the small change in per-
cent InAs across exposure levels, it is
unclear how an increased concentration of
MMA relative to DMA would contribute
significantly to an increased risk of arsenic-
induced health effects. Although it has been
suggested that during methylation a highly
reactive intermediate form ofMMA may be
formed (26), the existence of this hypo-
thetical chemical has not been demonstrat-
ed. Laboratory studies in vitro (43,44) and
in animals (45) show that although MMA
appears to be twice as potent as DMA in
genotoxicity and cytotoxicity tests, they are
both weak and far less toxic than the inor-
ganic forms. On the other hand, it has also
been postulated that an increase in DMA
may be more deleterious than previously
thought. In vitro studies found that DMA
can cause chromosomal damage (46,47);
similar studies were not reported for MMA.
A recent report of the study in Mexico indi-
cated that exposed individuals with skin
alterations had a higher MMA:DMA ratio
than exposed persons without skin effects
(34). However, the exposure magnitude of
the two groups was not reported, and the
possibility that overall higher exposures to
InAs or longer duration of exposure could
account for the signs of arsenicism cannot
be excluded.
A new hypothesis proposes that compe-
tition for methyl groups between arsenic
metabolism and DNA methylation could
lead to DNA hypomethylation, which has
been associated with the changes in gene
transcription found in epithelial cancers
(48). For this competition to occur, there
would have to be a limited availability of
methyl groups. Animal studies show that
the bioavailability of S-adenosylmethion-
ine, the source of methyl groups for arsenic
methylation, is not a limiting factor for
methylation under normal in vivo condi-
tions (31), but it has been suggested that
high arsenic exposure may cause the
demand for methyl groups to exceed the
supply, particularly for individuals with a
diet poor in methionine (18). However, it
was estimated that exposures to an arsenic
concentration of 1800 pg/l in drinking
water would require only 1.5% of a per-
son's daily dietary intake of methyl source
for arsenic methylation (49), making it
unlikely that the supply of methyl groups
would be exceeded. Nevertheless, there
may be a limited supply of methyltrans-
ferases or other chemicals involved in both
arsenic and DNA methylation.
The large interindividual variability in
methylation ability, as well as the possible
ethnic differences, may be due to genetic
polymorphisms associated with methylating
enzyme activity. Inh eritance iS a major fac-
tor in individual variation in several methyl-
transferases involved in the biotransforma-
tion of many drugs (50), and the suscepti-
bility to some occupational exposures
appears to be associated with differences in
detoxification enzymes such as N-acetyl-
transferase and aryl hydrocarbon hydroxy-
lase (51). Genetic polymorphisms of the
still-uncharacterized arsenic methylation
enzymes may help explain the interindivid-
ual variation. Similar genetic differences
may exist in arsenic-specific binding pro-
teins, which are thought to decrease the
toxicity of InAs by decreasing its tissue
availability until it can be methylated (33).
Alternatively, because GSH is involved
in arsenic metabolism, genotypic differ-
ences in the activity of glutathione trans-
ferases (GSTs), which catalyze the conjuga-
tion of GSH to a variety of carcinogens
and are part of the protective mechanism
against cancer caused by environmental
carcinogens (52), may affect methylation
ability. For example, the null genotype for
one of these enzymes, GSTM 1, varies from
30% to 70% depending on ethnicity (27).
In conclusion, the factors investigated
did not contribute to biologically meaning-
ful differences in the percentage of InAs in
urine. The large biomarker study presented
here in a chronically highly exposed popu-
lation indicates that, at high levels of
arsenic exposure, there is no evidence of a
plateau saturation effect and that variations
in methylation capacity, at least as reflected
by urinary metabolites, can be quite large.
Arsenic exposure level and duration, sex,
smoking, and ethnicity were associated
with differences in the MMA:DMA ratio,
together explaining about 30% of the total
variation. It is possible that several genetic
polymorphisms operating in the mecha-
nisms of arsenic detoxification play a role
in determining methylation capacity, along
with other exogenous factors such as diet
and other concurrent exposures. The sig-
nificance of the differences in MMA:DMA
ratio in relation to arsenic exposure and to
sex and smoking warrants further study,
since at present there is no clear evidence of
their relevance to health risks. In general,
given the current gaps in understanding the
mechanisms of arsenic detoxification, sev-
eral lines of research need to be continued
and pursued to confirm or reject some of
the more recently proposed hypotheses.
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Seventh
North American
ISSX Meeting
October 20-24, 1996
The Seventh North American Meeting of the International Society for the Study of Xenobiotics
(ISSX) will take place in San Diego, California from October 20-24, 1996 at the historic Hotel del
Coronado.
The meeting will feature plenary lectures, symposia, poster sessions, continuing education, com-
mercial exhibits and presentations.
Scientific Program
Scientific Program will highlight these themes:
Enzymology of xenobiotic biotransformation
FMO and P450
Hydrolytic enzymes
Conjugating enzymes
Human drug metabolism and polymorphisms
In vitro test systems and methodologies
Enzyme induction
Drug development and safety evaluation
Environmental and agricultural chemicals
Cosmetic and food chemicals
Biotechnology products
Regulatory affairs
For more information:
ISSX
PO Box 3
Cabin John, MD 20818 USA
FAX: 301-983-5357
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